† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
Background. The presence of transmitted drug resistance mutations (TDRMs) in antiretroviral treatment (ART)–naive patients can adversely affect the outcome of ART. Methods. Resistance testing was ...
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...
Please provide your email address to receive an email when new articles are posted on . Rates of both individual mutations and clinically relevant transmitted drug resistance were low among people ...
Michael Sension, MD, provides insights on resistance mechanisms promoting MDR HIV. Ryan Haumschild, PharmD, MS, MBA: If you could, give us an overview and then discuss how this smaller patient ...
Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback